GSK's 2015 Discovery Fast Track Challenge seeks early drug discovery partnerships
GlaxoSmithKline is encouraging academic scientists in Europe, Canada and the U.S. to submit their novel early drug discovery research proposals into its third annual Discovery Fast Track Challenge—a program designed to accelerate the translation of early-stage research into game-changing new medicines. The challenge provides a new template for drug discovery as it seeks to rapidly uncover the best opportunities for discovery research.
Scientists who participate in the challenge are asked to submit details about the biological targets or pathways they are researching and the scientific rationale detailing how this early-stage research could direct future drug development. Up to 12 proposals will be selected, across all regions, based on the strength of the scientists' hypotheses, originality, initial progress and the ability to deliver on an unmet medical need.
Scientists whose entries are selected will collaborate with GSK's Discovery Partnerships with Academia (DPAc) and Molecular Discovery Research teams to test their hypotheses on potential disease pathways or targets against GSK's extensive library of compounds. If a compound is identified during this process that shows activity against these pathways or targets, and could form the starting point for the development of a new medicine, the winning investigators could be offered a formal DPAc partnership and opportunity to work together on the development of a potential new medicine.
Carolyn Buser, global head of Discovery Partnerships with Academia (DPAc) at GSK, said, "The Discovery Fast Track Challenge is a unique opportunity to integrate the deep biological expertise found in academia with the extensive drug development knowledge of GSK. Winning ideas are translated into a high throughput screen to identify tool compounds for additional proof-of-concept studies. Pending the results and the interests from both academia and GSK, the collaboration may be extended to a long-term partnership to jointly develop therapeutics for the benefit of patients worldwide."
Since its initial launch in 2013, the annual challenge has attracted more than 500 proposals from more than 300 universities, academic research institutions and hospitals in the U.S., Canada and Europe. Previous entries have focused on a broad range of disease areas, including malaria, antibiotic resistance and certain types of cancer.
Launched in the U.K. in late 2010, DPAc is a new approach to drug discovery where academic partners become core members of drug-hunting teams. GSK and the academic partner share the risk and reward of innovation, where GSK funds activities in the partner laboratories, as well as providing in-kind resources to progress a programme from an idea to a candidate medicine. The DPAc model now is being used by GSK globally. To date, GSK has initiated 15 collaborations in 15 disease areas worldwide.
Registering for the challenge involves submitting a one-page summary of a novel drug discovery concept, including non-proprietary details of the biological target. An expert panel of judges from GSK will select a group of up to 30 finalists to present their proposals in person.
Registration is open through April 24.